NCT06181617Completed
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Source: ClinicalTrials.gov · Last updated 22 Jul 2025
Brief summary (registry, in English)
This cross-sectional, non-interventional study will assess health-related quality of life in in patients with hypertrophic cardiomyopathy in Japan. The study consists of two phases. Phase I is a qualitative study using semi-structured in-depth interviews in participants with hypertrophic cardiomyopathy. Phase II is a quantitative study using questionnaires in participants with hypertrophic cardiomyopathy and a control group of participants who do not have hypertrophic cardiomyopathy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 149 (actual)
- First submitted
- 13 Dec 2023
- Start date
- 6 Dec 2023
- Primary completion date
- 16 May 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06181617
What you commit to
- Study type: Observational
- Participants enrolled: 149
- From 6 Dec 2023 to the primary completion date, 16 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have previously participated or are currently participating in another clinical trial (not including observational studies)
- Participants who have previously participated or are currently participating in another clinical trial (not including observational studies)
Other illness
- Participants who have ever been diagnosed with dilated cardiomyopathy or secondary cardiomyopathy, including cardiac amyloidosis, Fabry disease, or mitochondrial myopathy
- Participants who have ever been diagnosed with either dilated cardiomyopathy or secondary cardiomyopathy, including cardiac amyloidosis, Fabry disease, or mitochondrial myopathy
Other
- Participants who have ever been diagnosed with non-obstructive or obstructive HCM
Who the study is looking for
- Participants diagnosed with non-obstructive or obstructive HCM in Japan
- Participants aged ≥18 years of age
- Participants who have been attending outpatient visits for HCM and who are referred to the study by the physician treating HCM
- Participants with HCM who are diagnosed as New York Heart Association (NYHA) functional classification 2-3 at enrolment
- Participants experiencing burden in their daily lives because of HCM (self-reported)
- Participants aged ≥18 years of age
- Individuals from the general population who are enrolled in 3H Clinical Trial's consumer panel
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Minato-ku | Japan | Unknown status |
Related publications
- Physical activity and quality of life in patients with hypertrophic cardiomyopathy in Japan: a quantitative study.Future Cardiol · 2026 · PMID 42870498
This page is information, not medical advice. Discuss any trial with your doctor.